Literature DB >> 9774463

Different classes of coactivators recognize distinct but overlapping binding sites on the estrogen receptor ligand binding domain.

F C Eng1, A Barsalou, N Akutsu, I Mercier, C Zechel, S Mader, J H White.   

Abstract

We have analyzed interaction of coactivators with the wild-type estrogen receptor alpha (ER), HEG0, and a mutant, L536P-HEG0, which is constitutively active in several transiently transfected cells and a HeLa line that stably propagates an estrogen-sensitive reporter gene. Different classes of coactivators do not recognize the ER ligand binding domain (LBD) in the same manner. Steroid receptor coactivator-1 (SRC-1), amplified in breast cancer-1 (AIB-1), transcriptional intermediary factor-1 (TIF-1), transcriptional intermediary factor-2 (TIF-2), and receptor interacting protein 140 (RIP140) interacted with HEG0 and L536P-HEG0 in the presence of estradiol, but generally not in the presence of anti-estrogens. However, ICI164,384 stimulated some interaction of RIP140 with LBDs. SRC-1, AIB-1, and RIP140 interacted constitutively with the L536P ER, whereas TIF-1 and TIF-2 interacted only weakly in the absence of hormone. Reciprocal competition for binding to the ER LBD was observed between different classes of coactivators. Moreover, coexpression of RIP140 blocked enhanced transactivation by HEG0 observed in the presence of TIF-2, suggesting that RIP140 may play a negative role in ER signaling. We conclude that constitutive activity of L536P-HEG0 is manifested to similar degrees in different cell types and likely arises from constitutive coactivator binding; different classes of coactivators recognize distinct but overlapping binding sites on the ER LBD. Finally, the observation that L536P-HEG0 interacted constitutively with AIB-1, a coactivator that has been implicated in ER signaling in breast and ovarian cancer, suggests that similar mutations in the ER may contribute to hormone-independent proliferation of breast and ovarian cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9774463     DOI: 10.1074/jbc.273.43.28371

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  DT56a stimulates creatine kinase specific activity in vascular tissues of rats.

Authors:  D Somjen; I Yoles
Journal:  J Endocrinol Invest       Date:  2003-10       Impact factor: 4.256

2.  Single-chain estrogen receptors (ERs) reveal that the ERalpha/beta heterodimer emulates functions of the ERalpha dimer in genomic estrogen signaling pathways.

Authors:  Xiaodong Li; Jing Huang; Ping Yi; Robert A Bambara; Russell Hilf; Mesut Muyan
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

3.  Estradiol repression of tumor necrosis factor-alpha transcription requires estrogen receptor activation function-2 and is enhanced by coactivators.

Authors:  J An; R C Ribeiro; P Webb; J A Gustafsson; P J Kushner; J D Baxter; D C Leitman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

4.  The nuclear receptor transcriptional coregulator RIP140.

Authors:  Patrick Augereau; Eric Badia; Sophie Carascossa; Audrey Castet; Samuel Fritsch; Pierre-Olivier Harmand; Stéphan Jalaguier; Vincent Cavaillès
Journal:  Nucl Recept Signal       Date:  2006-10-30

5.  The molecular basis of the interaction between the proline-rich SH3-binding motif of PNRC and estrogen receptor alpha.

Authors:  Dujin Zhou; Jing Jing Ye; Yuping Li; Ki Lui; Shiuan Chen
Journal:  Nucleic Acids Res       Date:  2006-10-26       Impact factor: 16.971

6.  Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer.

Authors:  A Harrod; J Fulton; V T M Nguyen; M Periyasamy; L Ramos-Garcia; C-F Lai; G Metodieva; A de Giorgio; R L Williams; D B Santos; P J Gomez; M-L Lin; M V Metodiev; J Stebbing; L Castellano; L Magnani; R C Coombes; L Buluwela; S Ali
Journal:  Oncogene       Date:  2016-10-17       Impact factor: 9.867

7.  Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer.

Authors:  Isabel Mayayo-Peralta; Beatrice Faggion; Liesbeth Hoekman; Ben Morris; Cor Lieftink; Isabella Goldsbrough; Lakjaya Buluwela; Joseph C Siefert; Harm Post; Maarten Altelaar; Roderick Beijersbergen; Simak Ali; Wilbert Zwart; Stefan Prekovic
Journal:  Cancers (Basel)       Date:  2021-12-16       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.